De-Risking Highly Potent APIs & Hazardous New Modalities

Marry Next Generation Formulation, Process Development & Manufacturing with World-Leading EHS & Toxicology for Safety & Product Quality

Just Some of the Engaging Sessions from 2022

1280px-World_Health_Organization_Logo.svg
hpapi image.png

On GMP Inspection Excellence for Highly Potent API Manufacturing, Introduction to WHO Prequalification Programme (PQP) and inspections of pharmaceutical manufacturers for WHO PQP.

On Creating and Utilizing an Interactive Virtual Reality Environment in the Facility Design of the Future for High Potent APIs& on the Classification and Hazard Assessment of New Modalities, ADCs & PDCs.

hpapi lily.png

On Evaluating Risk Curves in Pharma for Product Quality, Extractables & Leachables in HPAPI, and the Integration of Advanced Manufacturing Technologies in Small Molecule High Potent Drug Production.

abbvie.png

On Tech Transfer and Scale-up of Potent Drug-Linkers and ADCs, Contrasting Internal vs External Manufacturing.

hpapi usp

On the challenges of Nitrosamine impurities and case study on analytical approaches for risk assessment.

 

Snapshot of 2022's Attending Organizations:

takeda_logo
gilead logo
astrazeneca
Merck_Logo.svg
Logo_Bayer.svg
hpapi lily.png
abbvie.png
hpapi usp

 

Check out Outsourced Pharma's Brand New E-Book: